Skip to content

Advertisement

Population Health Metrics

What do you think about BMC? Take part in

Open Access
Open Peer Review

This article has Open Peer Review reports available.

How does Open Peer Review work?

Epidemiology of dyslipidemia in Chinese adults: meta-analysis of prevalence, awareness, treatment, and control

Population Health Metrics201412:28

https://doi.org/10.1186/s12963-014-0028-7

Received: 12 March 2014

Accepted: 1 October 2014

Published: 28 October 2014

Abstract

Background

Numerous epidemiology studies on dyslipidemia have been conducted in China. However, a nationally representative estimate for dyslipidemia prevalence is lacking. The aim of this study is to appraise the nationwide prevalence, awareness, treatment, and control rates of dyslipidemia in adults in China.

Methods

We performed a systematic review of the related observational studies published since 2003 by searching English and Chinese literature databases. Meta-analyses were conducted in eligible studies using a random effect model to summarize the dyslipidemia prevalence, awareness, treatment, and control rates. Heterogeneity and publication bias were analyzed. Sensitivity analyses were performed to explain heterogeneity and examine the impact of study quality on the results of meta-analyses.

Results

Thirty-eight papers were included for meta-analyses, with a total sample size of 387,825. The prevalence, awareness, treatment, and control rates of dyslipidemia were 41.9% (95% CI: 37.7% - 46.2%), 24.4% (95% CI: 14.4% - 38.4%), 8.8% (95% CI: 7.7% - 10.0%), and 4.3% (95% CI: 4.1% - 4.5%), respectively. The prevalence of hypercholesterolemia, hypertriglyceridemia, mixed hyperlipidemia, low levels of high-density lipoprotein cholesterol, and high levels of low-density lipoprotein cholesterol were 10.1% (95% CI: 5.8% - 16.9%), 17.7% (95% CI: 14.0% - 22.1%), 5.1% (95% CI: 3.1% - 8.2%), 11.0% (95% CI: 8.0% - 15.0%), and 8.8% (95% CI: 4.1% - 17.8%), respectively. Sensitivity analyses revealed that males had a higher prevalence of dyslipidemia (43.2%) than females (35.6%). Study samples of age 30 and above in the eastern region tended to have higher prevalence of dyslipidemia. The quality of the studies has a slight impact on the pooled estimates.

Conclusions

The overall pooled prevalence of dyslipidemia in Chinese adults was estimated to be 41.9%, with males having a higher rate than females.

Keywords

DyslipidemiaPrevalenceAwareness rateTreatment rateControl rateMeta-analysis

Introduction

Dyslipidemia represents one of the major risk factors for atherosclerosis affecting arteries of large and medium size and consequently causing ischemia in the brain, heart, or legs. Coronary artery disease and cerebral stroke represent the major causes of morbidity and mortality among elderly and middle aged subjects [1]. The prevalence of dyslipidemia has increased dramatically in Chinese cities with lifestyle changes over the past decade, and cardiovascular diseases have emerged as a leading cause of death in Chinese adults [2].

Surveys investigating the epidemiological data of dyslipidemia in Chinese adults have been published, but the results vary due to diverse populations of different regions and the use of different diagnosis criteria [2]. An overall appraisal of dyslipidemia epidemiology nationwide in China would potentially benefit future research and policy discussions. We therefore performed meta-analyses by a comprehensive systematic review of all available evidence to synthesize the current dyslipidemia prevalence, awareness, treatment, and control among Chinese adults.

Methods

Search strategy and eligibility criteria

Based on the MOOSE guideline [3], we identified epidemiological studies on dyslipidemia in Chinese adults published in English or Chinese between January 2003 and August 2013. The search strategy comprised of a search of Western electronic databases (including Medline, Embase, and CINAHL) and a search of Chinese databases (including SinoMed, CNKI, and Wanfang Data). We used the search terms "dyslipidemia", "hyperlipidemia", "epidemiology", "incidence", "prevalence", "awareness rate", "treatment rate", "control rate", "China or Chinese", and these terms' variants and combinations.

Eligible studies had to have reported any of the following epidemiological data related to dyslipidemia in sampled populations of Chinese subjects: prevalence, awareness rate, treatment rate, and control rate. The diagnosis criteria was based on the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults [2], which defined dyslipidemia as any one of the following four conditions: hypercholesterolemia (total cholesterol (TC) ≥ 6.22 mmol/L); hypertriglyceridemia (triglycerides (TG) ≥2.26 mmol/L); low levels of high-density lipoprotein cholesterol (HDL-C < 1.04 mmol/L); high levels of low-density lipoprotein cholesterol (LDL-C ≥ 4.14 mmol/L).

Dyslipidemia awareness was defined as a self-report of any prior laboratory diagnosis of dyslipidemia. Treatment was defined broadly as interventions including medication, diet, exercise, and monitoring to manage dyslipidemia. Participants were considered to have controlled dyslipidemia if their serum TC, TG, LDL-C, and HDL-C were within the normal ranges as defined above based on the 2007 Chinese guidelines.

We also applied the following exclusion criteria in filtering the identified publications:

  • Non-human studies

  • Non-research based publications such as press releases, newsletters, forum discussions, etc.

  • Non-epidemiological studies such as basic science research on dyslipidemia.

  • Studies that did not disclose when the data was collected, sample size, or denominator for each reported prevalence or rate.

  • Studies that investigated specific populations such as military, prisoners, specific ethnic groups, etc.

  • Studies that did not apply the diagnosis criteria published in the 2007 Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults.

Study identification and data extraction

We identified relevant studies by searching electronic databases, scanning reference lists, and consulting clinical experts in dyslipidemia. Additionally, studies presented at key conference proceedings were identified. Two reviewers independently examined all the titles and abstracts of the studies retrieved from the searches for potentially eligible studies, then the full text of all potentially relevant citations were obtained and independently assessed by the reviewers to confirm whether they met the inclusion criteria. The results were checked and discussed by the two reviewers to agree upon a final list of included studies.

Using a standardized and predesigned data collection form, all relevant data in each included paper were extracted by two reviewers independently. The data extracted were cross-checked and any unresolved discrepancies were referred to a third reviewer. Where necessary, inputs of a clinical expert advisor were solicited to facilitate discussions among the reviewers.

For each included study, we extracted general information (including authors, year, title, type of publication, etc.), study characteristics (including study design, population, location, diagnosis criteria, sample size, etc.), participants' characteristics (including age, sex, type of dyslipidemia, etc.). We further recorded the numbers of people with any one type of dyslipidemia condition and reported awareness, treatment, and control rates. The data stratified by sex and dyslipidemia types, where available, were also extracted.

To inform the appropriateness of included studies in the meta-analysis and later evaluate the strength of the evidence, the two reviewers independently assessed and agreed on the quality of each included study using the quality assessment checklist for epidemiological studies [4]. The checklist assesses the quality of studies on a scale of 0 (the worst) to 18 (the best) using predefined criteria on both internal and external validities [4].

Statistical analyses and heterogeneity test

Pooled estimates of the dyslipidemia prevalence, awareness rate, treatment rate, and control rate and their corresponding 95% confidence intervals (CI) were calculated based on the random effect model [5] and stratified by sex and age group (over 18 or over 30 years) where applicable. Heterogeneity between studies was evaluated with the Cochran's Q test and I2 statistic, which describes the percentage of variation across studies (values of 25%, 50%, and 75% indicate low, moderate, and high degrees of heterogeneity, respectively) [6],[7]. Subgroup analyses were performed to investigate potential sources of heterogeneity from different geographical regions and types of dyslipidemia. Publication bias was evaluated by using the funnel plots method. Furthermore, sensitivity analyses were performed to evaluate the influence of particular study on a pooled estimate, which was recalculated by omitting a study each time. Independent or paired t-tests were used as appropriate, and a significant difference was reported if the p-value was less than 0.05. All statistical analyses were performed using SPSS version 20.0 (SPSS Inc, Chicago, USA) and Comprehensive Meta-Analysis software version 2.0 (Biostat, Englewood, USA).

Results

Characteristics of included studies

Our searches retrieved 7669 citations. Of these, 6800 were excluded after reading the abstracts, and 831 were further excluded after assessing the full papers, leaving 38 eligible papers for inclusion in our review and analyses (Figure 1) [8]-[45], which involved a total of 387,825 Chinese people.
Figure 1

Flow chart of screening and inclusion of studies for review and analysis.

Among the 38 included papers, 36 were written in Chinese and two were written in English; 33 studies were cross-sectional surveys and five studies employed census surveys or other designs; 18 studies were conducted in eastern China, 10 studies were conducted in central China, eight studies were conducted in western China, and two surveys crossed regions nationwide (Table 1) [8]-[45].
Table 1

Characteristics of included studies

Author

Year

Region

Age range

Number of participants

Number of patients diagnosed with dyslipidemia

Score of quality assessment

Luo R

2009

Chongqing

18-59 y

20000

6464

12

Guo MH

2011

Beijing

18-79 y

6790

3231

10

Li Y

2008

Beijing

18-79 y

2776

1269

15

Luo WP

2010-2011

Xinjiang

≥ 18 y

2999

2277

14

You AG

2007-2008

Henan

≥ 18 y

20194

-

15

Li JH

2010

National

≥ 18 y

97409

-

15

Mo J

2010

Guangdong

≥ 18 y

3577

2173

16

Pang QY

2006

Henan

≥ 18 y

984

314

9

Pang QY

2007

Henan

≥ 18 y

10127

4392

11

Li JH

2010

National

≥ 18 y

97409

51818

15

Chen YY

2010

Jiangxi

≥ 18 y

3000

1821

14

Zhang XW

2010

Zhejiang

≥ 18 y

17437

8694

14

Li XH

2007-2008

Gansu

> 18 y

3038

793

14

Hu XL

-

Zhejiang

> 18 y

2036

-

12

Li SL

2007-2008

Shanxi

20-74 y

1286

459

14

Gao B

2007-2008

Shanxi

20-74 y

3298

1106

15

Jin LZ

2007

Guangdong

20-74 y

1134

-

12

Li J

2009

Beijing

20-78 y

4332

1008

13

Wang JH

2007

Beijing

≥ 20 y

10054

-

13

Fu YY

2007

Beijing

≥ 20 y

10054

3373

16

Yin L

2008-2009

Hunan

> 20 y

1544

695

8

Fu YY

2007

Beijing

> 20 y

9786

3347

14

Guang ZJ

2011

Beijing

21-91 y

3340

993

14

Liu XY

2008

Ningxia

≥ 25 y

1275

619

14

Yuan XH

-

Guangdong

> 30 y

1053

465

8

Liao XY

2010

Sichuan

35-70 y

2032

474

14

Wang CJ

-

Henan

35-78 y

16926

7480

14

Shao YQ

2008

Zhejiang

> 35 y

7194

-

15

Zhou WJ

2008-2009

Jiangsu

> 35 y

2102

922

14

Li J

2009

Shandong

> 35 y

1972

-

15

Li Y

2008

Hubei

> 35 y

9865

2794

16

Gao Y

2011

Jilin

40-70 y

1332

618

12

Liu DW

-

Henan

≥ 45 y

4779

-

12

Zhao YZ

-

Sichuan

> 45 y

200

113

11

Wu ZF

2007-2008

Tianjin

50-94 y

1424

-

11

Sheng L

2009

Beijing

> 60 y

2685

-

13

Hu XZ

2007

Henan

> 60 y

1247

347

13

Liang YQ

2011

Guangdong

> 60 y

1135

680

12

Study quality was assessed for the 38 included papers. Four papers had quality scores between eight and 10 points, 13 papers had scores between 11 and 13 points, and 21 papers had scores between 14 and 16 points. Overall study quality was upper-middle and high, and the study quality did not differ significantly among the included studies.

Prevalence of dyslipidemia

Twenty-eight papers reported the total numbers of participants in the studies and those who were diagnosed with dyslipidemia (Figure 2). The pooled prevalence of dyslipidemia in Chinese adults was 41.9% (95% CI: 37.7% - 46.2%). The t-tests showed there were no statistically significant differences between subgroups stratified by age and geographic region (Tables 2 and 3); however, the pooled prevalence of dyslipidemia in males (43.2%) was higher than in female (35.6%) with statistical significance (t = 3.08, p < 0.05).
Figure 2

Forest plot of 28 studies' reported prevalence of dyslipidemia.

Table 2

Prevelance of dyslipidemia by different age groups

Age range

Number of studies

Total numbers of participants

Median (%)

Minimum (%)

Maximum (%)

Pooled prevalence (%) (95% CI)

≥ 18 y

19

203052

43.4

23.3

75.9

42.4 (37.2 ~ 47.7)

≥ 30 y

9

35892

44.2

23.3

59.9

40.9 (33.7 ~ 48.5)

Total

28

238944

44

23.3

75.9

41.9 (37.7 ~ 46.2)

Table 3

Prevalence of dyslipidemia by different regions and sexes

Groups

 

Number of studies

Total number of participants

Median (%)

Minimum (%)

Maximum (%)

Pooled prevalence (%) (95% CI)

≥ 18 y

       

Sex

Male

15

80145

44.3

25.8

68.9

45.6 (40.0 ~ 51.4)

 

Female

15

96864

33.7

14.6

56.4

35.9 (29.5 ~ 42.8)

Region

Eastern China

8

58092

40

23.3

60.7

40.0 (32.6 ~ 47.9)

 

Central China

4

15655

44.2

31.9

60.7

45.1 (35.2 ~ 55.5)

 

Western China

6

31896

34.6

26.1

75.9

41.9 (28.9 ~ 56.1)

≥ 30 y

       

Sex

Male

3

5442

26.2

24.9

45.3

31.5 (20.7 ~ 44.8)

 

Female

3

7772

30.2

29.9

43

34.1 (26.1 ~ 43.3)

Region

Eastern China

3

4290

44.2

43.9

59.9

49.3 (39.4 ~ 59.3)

 

Central China

4

29370

36.3

27.8

46.4

36.3 (26.6 ~ 47.1)

 

Western China

2

2232

39.9

23.3

56.5

38.5 (13.1 ~ 72.2)

Total

       

Sex

Male

18

85587

43.7

24.9

68.9

43.2 (37.4 ~ 49.1)

 

Female

18

104636

32.7

14.6

56.4

35.6 (30.0 ~ 41.7)

Region

Eastern China

11

62382

44.2

23.3

60.7

42.5 (36.1 ~ 49.2)

 

Central China

8

45025

43.8

27.8

60.7

40.6 (33.9 ~ 47.7)

 

Western China

8

34128

34.6

23.3

75.9

41.0 (30.0 ~ 53.0)

In terms of the different types of dyslipidemia, the pooled prevalence estimates of hypercholesterolemia (TC), hypertriglyceridemia (TG), mixed hyperlipidemia (TC + TG), low levels of high-density lipoprotein cholesterol (HDL-C), and high levels of low-density lipoprotein cholesterol (LDL-C) are 10.1% (95% CI: 5.8% - 16.9%), 17.7% (95% CI: 14.0% - 22.1%), 5.1% (95% CI: 3.1% - 8.2%), 11.0% (95% CI: 8.0% - 15.0%), and 8.8% (95% CI: 54.1% - 17.8%), respectively. There were no significant differences between age groups within each type of dyslipidemia condition (Table 4 and Additional file 1).
Table 4

Prevelance of dyslipidemia by different dyslipidemia types

Types

Age group

Number of studies

Total number of participants

Median (%)

Minimum (%)

Maximum (%)

Pooled prevalence (%) (95% CI)

Hypercholesterolemia (TC)

≥ 18 y

9

143350

7.7

2.5

41.8

7.9 (4.6 ~ 13.2)

≥ 30 y

10

41366

10.8

4.9

48.1

12.5 (5.8 ~ 25.0)

Total

19

184716

8.2

2.5

48.1

10.1 (5.8 ~ 16.9)

Hypertriglyceridemia (TG)

≥ 18 y

9

143350

15.3

4.5

36.9

13.7 (10.7 ~ 17.4)

≥ 30 y

10

41367

18.8

11.7

44.5

22.1 (16.0 ~ 29.7)

Total

19

184717

17.1

4.5

44.5

17.7 (14.0 ~ 22.1)

Mixed hyperlipidemia (TC + TG)

≥ 18 y

3

11249

6.5

1.9

4.2

4.8 (2.4 ~ 9.2)

≥ 30 y

1

2102

-

-

-

-

Total

4

13351

6.4

1.9

8.3

5.1 (3.1 ~ 8.2)

Low blood high-density lipoprotein cholesterol (HDL-C)

≥ 18 y

9

143350

6.9

0.2

57.3

11.0 (6.9 ~ 16.9)

≥ 30 y

9

38129

10.1

1.6

32.8

11.0 (6.6 ~ 17.9)

Total

18

181479

10

0.2

57.3

11.0 (8.0 ~ 15.0)

High blood low-density lipoprotein cholesterol (LDL-C)

≥ 18 y

5

130826

3.1

2.3

67.5

7.6 (2.1 ~ 24.3)

≥ 30 y

7

29843

12.2

1.7

21.3

9.7 (4.5 ~ 19.8)

Total

12

160669

8.8

1.7

67.5

8.8 (4.1 ~ 17.8)

Dyslipidemia awareness, treatment, and control

Using the dyslipidemia awareness rates reported in four studies, we arrived at a pooled estimate of 24.4% (95% CI: 14.4% - 38.4%). Based on the reported dyslipidemia treatment rates in two studies, we estimated a pooled treatment rate of 8.8% (95% CI: 7.7% - 10.0%). There were no significant differences between males and females in terms of dyslipidemia awareness and treatment rates (Table 5). Only one paper reported a dyslipidemia control rate, which was 4.3% (3.1% for males and 5.5% for females).
Table 5

Dyslipidemia awareness and treatment rates

Groups

Number of studies

Total number of participants

Median (%)

Minimum (%)

Maximum (%)

Pooled prevalence (%) (95% CI)

Awareness rate

      

Male

3

28021

25

12.4

25.3

20.1 (11.2 ~ 33.3)

Female

3

28439

31.2

14.7

32.9

25.2 (13.0 ~ 43.1)

Total

4

59807

28.9

13.5

29.8

24.4 (14.4 ~ 38.4)

Treatment rate

      

Male

2

26620

7.2

6.8

7.6

7.6 (7.3 ~ 7.9)

Female

2

26467

10.9

9.2

12.5

10.6 (7.8 ~ 14.2)

Total

2

53087

9.1

8.4

9.7

8.8 (7.7 ~ 10.0)

Sensitivity analysis, publication bias and heterogeneity

Two studies were assessed with a quality score of eight, the lowest among the included studies. In the sensitivity analysis, omitting these two studies resulted in a slight change in the pooled dyslipidemia prevalence estimate, 41.7% from 41.9%. The pooled prevalence of TC, TG, HDL-C, and LDL-C changed to 9.4%, 17.0%, 10.7%, and 8.3% from 10.1%, 17.7%, 11.0%, and 8.8%, respectively. Funnel plots were produced for the prevalence of each type of dyslipidemia (see the Additional file 1). Asymmetric funnels suggest the possibility of publication bias. A moderate degree of heterogeneity was observed in the pooled dyslipidemia prevalence (I2 = 49.9%, Q = 1.00, P < 0.001), awareness rate (I2 = 49.9%, Q = 0.99, P < 0.001), and treatment rate (I2 = 38.0%, Q = 0.721, P = 0.098).

Discussion

Our systematic review included 38 observational studies conducted in the past decade, covering most of the regions in China, and involving a total of 387,825 participants, representing the adult Chinese population. The pooled estimates from the meta-analyses showed high prevalence of dyslipidemia and low awareness, treatment, and control rates. The study and results are timely, as currently there is a lack of published up-to-date nationwide epidemiological data of dyslipidemia to support the evidence-based approach and management of dyslipidemia in China.

The pooled estimate of dyslipidemia prevalence among Chinese adults is 41.9%, which has more than doubled in the last 10 years [46], approaching the reported prevalence of 53% from the US National Health and Nutrition Examination Survey 2003-2006 [47]. The observed increase of dyslipidemia prevalence in China could possibly be attributed to the increasingly aging population and dramatic lifestyle changes coupled with economic growth, especially changes in cigarette smoking, dietary, and alcohol drinking behaviors among the general population [48].

The study discovered that hypertriglyceridemia (TG) was the most prevalent form of dyslipidemia, with a pooled estimate of 17.7%, followed by low levels of blood high-density lipoprotein cholesterol (HDL-C) (11.0%), hypercholesterolemia (TC) (10.1%), high levels of low-density lipoprotein cholesterol (LDL-C) (8.8%), and mixed hyperlipidemia (TC + TG) (5.1%). As dyslipidemia is one of the well-established risk factors for cardiovascular diseases [47], these results highlight the extensive need for appropriate interventions, both clinical and non-clinical, to treat all types of dyslipidemia. In addition, other considerations such as improving general awareness about dyslipidemia among both patients and health care professionals and promoting healthy diet and lifestyles are equally important in designing and implementing relevant public health strategies.

We calculated and compared the pooled estimates of dyslipidemia prevalence in age groups over 18 years and over 30 years. No significant difference was found between these age groups across different types of dyslipidemia conditions. However, trends of higher prevalence of TC, TG, and LDL-C abnormalities were observed in studies of older participants (≥30 years old) compared to those studies that enrolled younger participants (≥18 years old). We observed the highest estimate at 49.3% (95% CI: 39.4-59.3) among all of the pooled prevalence estimates in people over 30 years old in the eastern region of China. Another study in China concluded that greater burden of diet-related chronic conditions including dyslipidemia has been observed in economically vibrant and highly urbanized areas [49], which are predominantly in the eastern coastal region. More economically developed areas tend to have better access to health care facilities, which might have contributed to diagnosis and hence higher reported prevalence rates in these studies among populations in the eastern region of China.

The systematic review showed that dyslipidemia is more common in men than in women, which is consistent with the findings from American population-based studies [50],[51]. There were no significant differences in awareness, treatment, and control rates between the groups of men and women in China. However, studies conducted in the US showed that dyslipidemia was treated and controlled less often in men than in women [50]. A possible explanation for the higher dyslipidemia prevalence observed in men could be their higher probability of cigarette smoking, alcohol, and consumption of foods high in cholesterol.

The quality of studies included in our systematic review were generally good, thus the sensitivity analysis did not demonstrate much difference in the results of meta-analyses when the studies with the lowest quality scores were removed in the analyses. We believe our searches were comprehensive, although the asymmetric funnel plots suggested the possibility of publication bias. The moderate heterogeneity observed could come from the different study settings and populations. We investigated possible sources and performed subgroup analyses, but that still inadequately explained the heterogeneity findings in this study. The recent research of heterogeneity suggested that I2 estimates need to be interpreted with caution when a meta-analysis only includes a limited number of events or trials, in particular when the number of studies for further subgroup analyses is small [52]. Nevertheless, these uncertainties indicate the need of a higher-quality national survey with larger samples with better represented coverage across China.

Our study has some limitations. First, all the included studies were published after 2007 as we used the Chinese Guidelines on Prevention and Treatment of Dyslipidemia in Adults, published in 2007, as the diagnosis criteria [2]. Studies published before 2007 were based on a different set of diagnosis criteria, and therefore have not been included in our meta-analyses. Secondly, we could not investigate the differences in dyslipidemia prevalence between rural and urban areas due to the limited information reported in the included studies. Furthermore, we would like to highlight that the meta-analysis results on awareness, treatment, and control rate need to be interpreted with caution, as the number of studies reporting the relevant data are relatively small.

Conclusions

The pooled estimate of dyslipidemia prevalence among Chinese adults was 41.9%, and hypertriglyceridemia (TG) is the most prevalent dislipidemia condition. The prevalence of dyslipidemia in males was higher than in females. Our study also showed low dyslipidemia awareness, treatment, and control rates in China.

Additional file

Declarations

Funding

This study has been funded by Pfizer Investment Co. Ltd., Beijing, China, including all costs associated with the development and the publishing of the present manuscript. Funding was not contingent upon publication of the manuscript.

Authors’ Affiliations

(1)
School of Public Health, Central South University
(2)
Pfizer Investment Co. Ltd, Outcomes Research
(3)
IMS Health Asia Pacific, 8 Cross Street, #21-01/02/03 PWC Building, Singapore, Health Economics & Outcomes Research

References

  1. Pisciotta L, Bertolini S, Pende A: Lipoproteins, stroke and statins. Curr Vasc Pharmacol 2013, [Epub ahead of print].Google Scholar
  2. Chinese guidelines on prevention and treatment of dyslipidemia in adults Zhonghua Xin Xue Guan Bing Za Zhi 2007,35(5):390-419.Google Scholar
  3. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000,283(15):2008-2012. 10.1001/jama.283.15.2008View ArticlePubMedGoogle Scholar
  4. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL: Prevalence of erectile dysfunction: a systematic review of population-based studies. Int J Impot Res 2002,14(6):422-432. 10.1038/sj.ijir.3900905View ArticlePubMedGoogle Scholar
  5. Schmidt FL, Oh IS, Hayes TL: Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol 2009,62(Pt 1):97-128. 10.1348/000711007X255327View ArticlePubMedGoogle Scholar
  6. Huedo-Medina TB, Sanchez-Meca J, Marin-Martinez F, Botella J: Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods 2006,11(2):193-206. 10.1037/1082-989X.11.2.193View ArticlePubMedGoogle Scholar
  7. Higgins JP, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses. BMJ 2003,327(7414):557-560. 10.1136/bmj.327.7414.557View ArticlePubMedPubMed CentralGoogle Scholar
  8. Chen YY, Zhu LP, Li A: Epidemiologic characteristics of dyslipidemia in Jiangxi province adults. Pract Prev Med 2013, 20: 234-236.Google Scholar
  9. Fu YY, Yu JM, Wang JH: Awareness factors analysis of abonormal blood lipid in Beijing communities. Chin J Pract Intern Med 2010, 1: 38-40.Google Scholar
  10. Fu YY, Yu JM, Wang JH: Current status of dyslipidemia among overweight and obese population in Beijing community. Chin J Cardiol 2010, 28: 562-566.Google Scholar
  11. Gao B, Chen F, Zhang YP: Cross-sectional survey of lipid level in adults orth of nof Qinlin in Shanxi. Chin J Arterioscler 2010, 10: 824-827.Google Scholar
  12. Gao Y, Liu YB, Li ZM: Relationships between lipid level and fat distribution in Jilin rural area middle-aged population. Chin J Gerontol 2013, 33: 2107-2109.Google Scholar
  13. Guan ZJ, Xia CY: The study of prevention and treatment on the incidence of dyslipidemia of rural population in medical examination in Beijing. Chin Foreign Med Res 2012, 10: 63-65.Google Scholar
  14. Guo MH, Han XY, Li Z: The survey about prevalent charateristics of common chronic diseases among adults in Beijing Chaoyang district. Chin J Prev Control Chronic Dis 2013, 21: 294-296.Google Scholar
  15. Hu XL, Xie HB, Xu WH: Dyslipidemia and associated risk factors among residents in the Baimashan Ecological Area of Suichang. Prev Treat Cardi -Cereb Vasc Dis 2012, 12: 201-203.Google Scholar
  16. Hu XZ, Wang ST, Liu ZS: Correlation of dyslipidemia distribution and chronic kidney disease in Zhengzhou older population. Chin J Gerontol 2011, 31: 3584-3586.Google Scholar
  17. Jin LZ, Huang RH, Wu WM: Investigation on status of lipid disorders and chronic noninfectious diseases aggregation in Doumen Rural area of Zhuhai city. J Sun Yat Sen Univ (Med Sci) 2009, 30: 151-154.Google Scholar
  18. Li J: Hypertension on Middle-Elderly City Community Residents in Taishan District of Tai’an City. Taishan Medical University, Tai’an, China; 2010.Google Scholar
  19. Li J, Zhang YJ, Sun YH: Investigation of chronic disease incidence in Beijing Sunhe area residents. Chin J Gen Pract 2011, 9: 600-601.Google Scholar
  20. Li JH, Wang LM, Li YC, Bi YF, Jiang Y, Mi SQ, Dai M, Xu Y, Ning G, Zhao WH: Epidemiologic characteristics of dyslipidemia in Chinese adults 2010. Zhonghua Yu Fang Yi Xue Za Zhi 2012,46(5):414-418.PubMedGoogle Scholar
  21. Li JH, Wang LM, Mi SQ, Zhang M, Li YC, Jiang Y, Xu Y, Dai M, Wang LH: Awareness rate, treatment rate and control rate of dyslipidemia in Chinese adults, 2010. Zhonghua Yu Fang Yi Xue Za Zhi 2012,46(8):687-691.PubMedGoogle Scholar
  22. Li SL, Yu JX, Zhang YL: Epidemiology of dyslipidemia in residents of Yan’an district. S China J Prev Med 2011, 37: 17-20.Google Scholar
  23. Li XH, Li L, Qiao Y: Epidemiologic analysis of dyslipidemia in adult Tibetan population in Tibet. Chin Circ J 2009, 24: 458-460.Google Scholar
  24. Li Y, Li WS, Qu WH: Investigation of prevalence rate of dyslipidemia among immigrant population of rural residents in three gorges reservoir area. Chin Med Herald 2012, 9: 108-112.Google Scholar
  25. Li Y, Zhai L, Wang HB: The status quo of common chronic diseases among adults in Beijing Haidian district. Chin J Prev Control Chronic Dis 2010, 18: 261-264.Google Scholar
  26. Liang YQ, Zhou YY, Wu YQ: Epidemiologic survey of dyslipidemia among residents aged ≥ 60 years in Rong-Gui community and relationship between dyslipidemia and inter-arm blood pressure difference. New Med 2013, 2: 97-100.Google Scholar
  27. Liao XY, Xu GF, Wu J: Epidemiological study of hyperlipidemia with cardiovascular risk factors in urban and rural communities. West China Med J 2013, 1: 14-17.Google Scholar
  28. Liu DW, Wan J, Liu ZS, Wang P, Cheng GY, Shi XZ: Association between dyslipidemia and chronic kidney disease: a cross-sectional study in the middle-aged and elderly Chinese population. Chin Med J (Engl) 2013,126(7):1207-1212.Google Scholar
  29. Liu XY, Liu L, Zhao Y: Investigation of dyslipidemia prevalence and risk factors in Yinchuan city adults. J Ningxia Med Univ 2011, 33: 27-31.Google Scholar
  30. Luo R, Wang YH, Wang XL: Distribution of dyslipidemia among adult residents in Chongqing. J Chongqing Med Univ 2010,25(7):1086-1088.Google Scholar
  31. Luo WP, Liu LX, Ma JP: The analysis about residents chronic disease and risk factors of behavior in Xinjiang monitoring stations in 2010. Bull Dis Control Prev (China) 2013, 28: 20-23.Google Scholar
  32. Mo JF, Song XL, Xu YJ: The correlation research of dyslipidemia prevalence and risk factors about in Guangdong province adults. S China J Prev Med 2013, 39: 11-17.Google Scholar
  33. Pang QY, Han B, You A: The Effect Evaluation and Research about Body Mass Index, Waist Circumference and Girth Ratio Predict Dyslipidemia. 1st Jinjiluyu Epidemilogy Symposium, Changzhi, China; 2008.Google Scholar
  34. Pang QY, Yu DH, Lu J: Distribution characteristics of dyslipedemia and related-risk factors in Henan rural residents. J Zhengzhou Univ (Med Sci) 2009, 44: 547-550.Google Scholar
  35. Shao YQ: Epidemiological study on lipid level and its abnormal rate of Wenzhou community population. Mod Pract Med 2011, 23: 22-25.Google Scholar
  36. Sheng L, Ye P, Xu RY: Dyslipidemia distribution characteristics of Beijing older male residents. Clin Focus 2011, 26: 1572-1574.Google Scholar
  37. Wang CJ, Li YQ, Li LL, Wang L, Zhao JZ, You AG, Guo YR, Li WJ: Relationship between resting pulse rate and lipid metabolic dysfunctions in Chinese adults living in rural areas. PLoS One 2012,7(11):e49347. 10.1371/journal.pone.0049347View ArticlePubMedPubMed CentralGoogle Scholar
  38. Wang JH, Hu DY, Fu YY: Prevalence of dyslipidemia and borderline dyslipidemia and other risk factors of coronary heart disease in residents from Beijing communities. Chin J Cardilol 2010, 38: 175-180.Google Scholar
  39. Wu ZF, Wang L, Ma GQ: Relationship between body mass index and blood lipid or blood pressure in Tianjin suburbs senile male cohort. Chin J Prev Control Chronic Non Commun Dis 2009, 17: 293-294.Google Scholar
  40. Yin L, Li GC, Liu LY: Intervention of main chronic disease and related factors in Hunan province community residents. Pract Prev Med 2011,18(6):1148-1150.Google Scholar
  41. You A: The Prevalence and Influencing Factors of Type 2 Diabetes Mellitus in a Rural Population of Henan Province. Zhengzhou University, Zhengzhou, China; 2009.Google Scholar
  42. Yuan XH: Investigation of the prevalence of hyperlipidaemia in Yunfu city. China Mod Med 2012, 9: 176-177.Google Scholar
  43. Zhang XW, Ye Z, Zhou D, Zhang J, Wang H, He QF, Fang L, Zhao M, Shu D, Hu R, Gong W: Prevalence of dyslipidemia and its distribution among adults, a cross-sectional study in Zhejiang. Dis Surveill 2012,27(5):395-399.Google Scholar
  44. Zhao YZ, Feng SG, Li GM: The epidemiological study on dyslipidemia in Nanchong community. Med J West China 2012, 24: 1948-1950.Google Scholar
  45. Zhou WJ, Zhu Y, Liu P: Epidemiology survey of dyslipidemia among residents in Wuxi City and its influence factors. Jiangsu J Prev Med 2012, 23: 20-22.Google Scholar
  46. Zhao WH, Zhang J, You Y, Man QQ, Li H, Wang CR, Zhai Y, Li Y, Jin SG, Yang XG: Epidemiologic characteristics of dyslipidemia in people aged 18 years and over in China. Zhonghua Yu Fang Yi Xue Za Zhi 2005,39(5):306-310.PubMedGoogle Scholar
  47. Toth PP, Potter D, Ming EE: Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol 2012,6(4):325-330. 10.1016/j.jacl.2012.05.002View ArticlePubMedGoogle Scholar
  48. Zhou B, Rao X, Dennis BH, Li Y, Zhuo Q, Folsom AR, Yang J, Li Y, Stamler J, Cao T, Guo C, Thomas RP, Zhao L, Liu X, Tian X, Zheng R: The relationship between dietary factors and serum lipids in Chinese urban and rural populations of Beijing and Guangzhou. PRC-USA Cardiovascular and Cardiopulmonary Research Group. Int J Epidemiol 1995,24(3):528-534. 10.1093/ije/24.3.528View ArticlePubMedGoogle Scholar
  49. Chen CM: Overview of obesity in Mainland China. Obes Rev 2008,9(Suppl 1):14-21. 10.1111/j.1467-789X.2007.00433.xView ArticlePubMedGoogle Scholar
  50. Goff DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM: Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 2006,113(5):647-656. 10.1161/CIRCULATIONAHA.105.552737View ArticlePubMedGoogle Scholar
  51. Taylor HA Jr, Akylbekova EL, Garrison RJ, Sarpong D, Joe J, Walker E, Wyatt SB, Steffes MW: Dyslipidemia and the treatment of lipid disorders in African Americans. Am J Med 2009,122(5):454-463. 10.1016/j.amjmed.2008.09.049View ArticlePubMedGoogle Scholar
  52. Thorlund K, Imberger G, Johnston BC, Walsh M, Awad T, Thabane L, Gluud C, Devereaux PJ, Wetterslev J: Evolution of heterogeneity (I2) estimates and their 95% confidence intervals in large meta-analyses. PLoS One 2012, 7: e39471. 10.1371/journal.pone.0039471View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© Huang et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement